Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, David E.; Camidge, D. Ross; Morgensztern, Daniel; Cetnar, Jeremey; Kelly, Ronan J.; Ramalingam, Suresh S.; Spigel, David R.; Jeong, Woondong; Scaglioni, Pier P.; Zhang, Song; Li, Marilyn; Weaver, David T.; Vaikus, Louis; Keegan, Mitchell; Horobin, Joanna C.; Burns, Timothy F.

doi:10.1016/j.lungcan.2019.10.033

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Objectives: KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need in thoracic oncology. Preclinical studies have demonstrated that KRAS mutant NSCLC cell lines and xenografts with additional alterations in either TP53 or CDKN2A (INK4A…